Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BioNexus Gene Lab Corp (BGLC) is the issuer named in a Schedule 13G reporting 392,329 common shares, or 13.4%, beneficially owned by Fidelion Diagnostics Pte. Ltd., Molecule Bio LLC, Rainy Morning Technology (Hong Kong) Limited, and Ling Xiao. These reports concern the same shares held directly by Fidelion, rather than four separate blocks. Fidelion reports sole voting and dispositive power; the other reporting persons report shared voting and dispositive power.
The 13.4% calculation uses 2,933,442 BGLC shares outstanding as reflected in the company’s Form 10-Q for the quarter ended June 30, 2026. The reporting persons disclaim group status except for their respective pecuniary interests.
Key Figures
Beneficially owned shares:392,329 sharesPercent of class:13.4%Shares outstanding:2,933,442 shares
3 metrics
Beneficially owned shares392,329 sharesReported for the same shares held directly by Fidelion Diagnostics Pte. Ltd.
Percent of class13.4%Reported by each reporting person
Shares outstanding2,933,442 sharesAs reflected in the Form 10-Q for the quarter ended June 30, 2026
Key Terms
beneficial ownership, Sole Voting Power, Shared Dispositive Power, pecuniary interest
4 terms
beneficial ownershipregulatory
"The beneficial ownership percentage is based on a total of"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole Voting Powerregulatory
"Sole Voting Power 392,329.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 392,329.00"
pecuniary interestregulatory
"except for their respective pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many BGLC shares do the Schedule 13G reporting persons report?
The reporting persons reported beneficial ownership of 392,329 BGLC common shares, equal to 13.4% of the class. The shares are held directly by Fidelion Diagnostics Pte. Ltd.; Fidelion reports sole voting and dispositive power, while the other reporting persons report shared voting and dispositive power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
BioNexus Gene Lab Corp
(Name of Issuer)
COMMON STOCK, NO PAR VALUE
(Title of Class of Securities)
090628306
(CUSIP Number)
11/28/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
090628306
1
Names of Reporting Persons
Fidelion Diagnostics Pte. Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SINGAPORE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
392,329.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
392,329.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
392,329.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons disclaim status as a "group" except for their respective pecuniary interest and this Report shall not be an admission that such Reporting Person is the beneficial owner of the securities for Section 16 of the Exchange Act, as amended, purposes or for any other purpose.
(2) The beneficial ownership percentage is based on a total of 2,933,442 shares of common stock, no par value per share, issued and outstanding as reflected in the Company's Form 10-Q for the three-month period ended June 30, 2026 filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
CUSIP Number(s):
090628306
1
Names of Reporting Persons
MOLECULE BIO LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
392,329.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
392,329.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
392,329.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.4 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons disclaim status as a "group" except for their respective pecuniary interest and this Report shall not be an admission that such Reporting Person is the beneficial owner of the securities for Section 16 of the Exchange Act, as amended, purposes or for any other purpose.
(2) Consists of shares held directly by Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The Reporting Person is a controlling shareholder of Fidelion and shares voting and dispositive power with respect to these shares.
(3) The beneficial ownership percentage is based on a total of 2,933,442 shares of common stock, no par value per share, issued and outstanding as reflected in the Company's Form 10-Q for the three-month period ended June 30, 2026 filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
CUSIP Number(s):
090628306
1
Names of Reporting Persons
XIAO LING
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SINGAPORE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
392,329.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
392,329.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
392,329.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.4 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons disclaim status as a "group" except for their respective pecuniary interest and this Report shall not be an admission that such Reporting Person is the beneficial owner of the securities for Section 16 of the Exchange Act, as amended, purposes or for any other purpose. (2) Consists of shares held directly by Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The Reporting Person is a controlling shareholder of Molecule Bio LLC and shares voting and dispositive power with respect to these shares. (3) The beneficial ownership percentage is based on a total of 2,933,442 shares of common stock, no par value per share, issued and outstanding as reflected in the Company's Form 10-Q for the three-month period ended June 30, 2026 filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
CUSIP Number(s):
090628306
1
Names of Reporting Persons
RAINY MORNING TECHNOLOGY (HONG KONG) LIMITED
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
HONG KONG
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
392,329.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
392,329.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
392,329.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons disclaim status as a "group" except for their respective pecuniary interest and this Report shall not be an admission that such Reporting Person is the beneficial owner of the securities for Section 16 of the Exchange Act, as amended, purposes or for any other purpose.
(2) Consists of shares held directly by Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The Reporting Person is a controlling shareholder of Fidelion and shares voting and dispositive power with respect to these shares.
(3) The beneficial ownership percentage is based on a total of 2,933,442 shares of common stock, no par value per share, issued and outstanding as reflected in the Company's Form 10-Q for the three-month period ended June 30, 2026 filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BioNexus Gene Lab Corp
(b)
Address of issuer's principal executive offices:
Unit A-28-7, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, 59000 Kuala Lumpur
Address or principal business office or, if none, residence:
-Fidelion Diagnostics Pte. Ltd.
10 Anson Road, #13-09
International Plaza
Singapore 079903
-Molecule Bio LLC
1309 Coffeen Avenue Ste 1200
Sheridan, Wyoming 82801
-Rainy Morning Technology (Hong Kong) Limited
Room 1804, 18/F, K11 Atelier, 18
Salisbury Road, Tsim Sha Tsui, Hong Kong
-Ling Xiao
Blk 100, Toa Payoh Lorong 1, #03-269
Singapore 310100
(c)
Citizenship:
Fidelion Diagnostics Pte. Ltd. - Singapore
Molecule Bio LLC - United States
Rainy Morning Technology (Hong Kong) Limited - Hong Kong
Ling Xiao - Singapore
(d)
Title of class of securities:
COMMON STOCK, NO PAR VALUE
(e)
CUSIP Number(s):
090628306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Amount beneficially owned: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
(b)
Percent of class:
Percent of class: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Sole power to vote or to direct the vote: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
(ii) Shared power to vote or to direct the vote:
Shared power to vote or to direct the vote: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
(iii) Sole power to dispose or to direct the disposition of:
Sole power to dispose or to direct the disposition of: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
(iv) Shared power to dispose or to direct the disposition of:
Shared power to dispose or to direct the disposition of: Incorporated by reference to Items 5-11 of the cover page pertaining to each reporting person.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
